A Consensus Conference was convened on November 16th, 1995, at the Ritz-Carlton Hotel, Phoenix, Arizona, with the specific aim of generating a consensus on three specific items: the definition of orthostatic hypotension, pure autonomic failure (Bradbury Eggleston syndrome, idiopathic orthostatic hypotension, progressive autonomic failure), and multiple system atrophy. The meeting was sponsored by the American Autonomic Society, and co-sponsored by the American Academy of Neurology. The following are the items on which consensus was reached.
Definition of orthostatic hypotension
Orthostatic hypotension (OH) is a reduction of systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of standing. It is a physical sign and not a disease. An acceptable alternative to standing is the demonstration of a similar drop in blood pressure within 3 minutes, using a tilt table in the head-up position, at an angle of at least 60 degrees.
Confounding variables to be considered when reaching a diagnosis should include: food ingestion, time of day, state of hydration, ambient temperature, recent recumbency, postural deconditioning, hypertension, medications, gender, and age.
Orthostatic hypotension may be symptomatic or asymptomatic. Symptoms of OH are those that develop on assuming the erect posture or following head-up tilt and usually resolve on resuming the recumbent position. They may include lightheadedness, dizziness, blurred vision, weakness, fatigue, cognitive impairment, nausea, palpitations, tremulousness, headache, and neck ache. If the patient has symptoms suggestive of, but does not have documented, orthostatic hypotension, repeated measurements of blood pressure should be performed. Occasional patients may not manifest significant falls in blood pressure until they stand for at least 10 minutes.
Pure autonomic failure (PAF)
Pure autonomic failure is an idiopathic sporadic disorder characterized by OH usually with evidence of more widespread autonomic failure. No other neurological features are present. Some patients with the manifestations of PAF may later prove to have other disorders such as multiple system atrophy. Reduced supine plasma norepinephrine levels are characteristic of PAF.
Parkinson's disease with autonomic failure
A minority of patients with Parkinson's disease as defined by United Kingdom Parkinson's Disease Brain Bank criteria 1 may also develop autonomic failure, including OH. It is not known if these patients have a more serious prognosis than Parkinson's disease without autonomic failure.
Multiple system atrophy (MSA)
MSA is a sporadic, progressive, adult onset disorder characterized by autonomic dysfunction, parkinsonism, and ataxia in any combination. The features of this disorder include:
Parkinsonism (bradykinesia with rigidity or tremor or both), usually with a poor or unsustained motor response to chronic levodopa therapy.
Cerebellar or corticospinal signs.
Orthostatic hypotension, impotence, urinary incontinence or retention, usually preceding or within 2 years after the onset of the motor symptoms.
Characteristically, these features cannot be explained by medications or other disorders. Parkinsonian and cerebellar features commonly occur in combination. However, certain features may predominate. When parkinsonian features predominate, the term striatonigral degeneration is often used. When cerebellar features predominate, sporadic olivopontocerebellar atrophy is often used. When autonomic failure predominates, the term Shy-Drager syndrome is often used. These manifestations may occur in various combinations and evolve with time.
Footnotes
-
Consensus Committee Participants include: Irwin J. Schatz, MD (Co-Chair), Department of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA; Sir Roger Bannister (Co-Chair), Pembroke College, Oxford, UK, Roy L. Freeman, MD, Division of Neurology, Deaconess Hospital, Boston, Massachusetts, USA; Christopher G. Goetz, MD, Department of Neurology, Rush Medical College, Chicago, Illinois, USA, Joseph Jankovic, MD, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA; Horacio C. Kaufmann, MD, Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA William C. Koller, MD, Department of Neurology, University of Kansas, Kansas City, Kansas, USA; Phillip A. Low, MD, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA; Christopher J. Mathias, MD, St. Mary's Hospital/Imperial College School of Medicine and the National Hospital/Institute of Neurology, Queen Square, London, UK, Ronald J. Polinsky, MD, Sandoz Research Institute, East Hanover, New Jersey, USA Niall P. Quinn, MD, Institute of Neurology, University Department of Clinical Neurology, The National Hospital, London, UK David Robertson, MD, Autonomic Dysfunction Center, Vanderbilt University, Nashville, Tennessee, USA, David H.P. Streeten, MD, Department of Medicine, Health Science Center, Syracuse, New York, USA.
- Copyright 1996 by the American Academy of Neurology
References
- 1.↵
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension
Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension
The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine
Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension